Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients
Status:
Terminated
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
We study if the administration of intralesional Adalimumab (directly injected in the
stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared
with placebo in patients with Crohn's disease who had confirmed intestinal stenosis (3
stenosis as maximum)